Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday

Source The Motley Fool

Key Points

  • The biotech reported its second-quarter earnings just after market close the previous day.

  • It topped analyst estimates on both the top and bottom lines.

  • These 10 stocks could mint the next wave of millionaires ›

Just after market close, Adaptive Biotechnologies (NASDAQ: ADPT) took the wraps off its second quarter. The following day, investors reacted to this by bidding the biotech company's stock up by almost 6%. That was far higher than the 0.7% lift of the S&P 500 index that day.

MRD for the win

The commercial-stage Adaptive booked $58.9 million in revenue for the period, a robust 36% improvement over the same quarter of 2024. Much of this growth was due to the company's efforts fighting minimal residual disease (MRD), a cancer disorder in which a relatively small number of cancer cells remain in the body -- and thus present a threat -- after medical treatment.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Two people participating in a telehealth session.

Image source: Getty Images.

Adaptive revealed that its MRD business was responsible for 85% of the quarter's revenue. Its take grew 42% year over year.

At the bottom of the profit and loss statement, Adaptive recorded a net loss of $25.6 million ($0.17 per share). This was much narrower than the more than $46 million deficit of 2024's Q2.

With those numbers, the company scored an easy twin beat on the consensus analyst estimates. Those folks were modeling only $49 million and change for revenue, and a significantly deeper net loss of $0.24 per share.

A key revenue stream should flow harder

On the back of that encouraging growth in the MRD sphere, Adaptive raised its guidance for both the revenue from that business and cash burn.

It now expects that MRD will bring in $190 million to $200 million across the entirety of 2025, up from its previous projection of $180 million to $190 million. It did not proffer any guidance for its other major revenue stream, immune medicine. As for cash burn, over the year, it should be $45 million to $55 million. The preceding forecast called for $50 million to $60 million.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

See the stocks »

*Stock Advisor returns as of August 4, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Bitcoin Bull Run at Risk as Whales Sell and Retail Buys In LateThe tug of war between Bitcoin bulls and bears since the asset reached its all-time high of $122,054 on July 14 has kept prices largely rangebound. 
Author  Beincrypto
Aug 08, Fri
The tug of war between Bitcoin bulls and bears since the asset reached its all-time high of $122,054 on July 14 has kept prices largely rangebound. 
placeholder
Gold Price Forecast: XAU/USD remains capped under $3,400 ahead of US inflation dataThe Gold price (XAU/USD) attracts some sellers to near $3,390 during the early Asian session on Monday.
Author  FXStreet
4 hours ago
The Gold price (XAU/USD) attracts some sellers to near $3,390 during the early Asian session on Monday.
placeholder
EUR/USD holds gains around 1.1650 due to cautious tone surrounding ECB outlookEUR/USD edges higher after registering losses in the previous session, trading around 1.1650 during the Asian hours on Monday.
Author  FXStreet
4 hours ago
EUR/USD edges higher after registering losses in the previous session, trading around 1.1650 during the Asian hours on Monday.
placeholder
Ethereum Surges Past $4,300 as Markets Await Pivotal CPI DataOver the weekend, Fed Vice Chair Michelle Bowman’s unexpected remarks fueled Ethereum’s surprise rise.
Author  Beincrypto
4 hours ago
Over the weekend, Fed Vice Chair Michelle Bowman’s unexpected remarks fueled Ethereum’s surprise rise.
placeholder
Top 3 Price Prediction: BTC nears record highs, ETH and XRP follow suitBitcoin (BTC), Ethereum (ETH), and Ripple (XRP) kicked off the week on a bullish note, with BTC inching closer to its record high of $123,218.
Author  FXStreet
2 hours ago
Bitcoin (BTC), Ethereum (ETH), and Ripple (XRP) kicked off the week on a bullish note, with BTC inching closer to its record high of $123,218.
goTop
quote